<p>How can healthcare providers best navigate the unique complexities of diabetes in an aging population? </p><p>Our host, <strong>Dr.</strong> <strong>Jeremy Gilbert</strong>, explores the multifaceted nature of type 2 diabetes management in the elderly with <strong>Dr. Peter Lin</strong>, Director of Primary Care Initiatives at the Canadian Heart Research Centre and contributing author to the Diabetes Canada Clinical Practice Guidelines. </p><p>In this episode, our experts delve into <strong>crucial considerations</strong> for managing diabetes in older people, including <strong>comorbidities, cognition, frailty, hypoglycemia risk</strong>, and the <strong>use of basal insulins</strong>. Hear our experts share their <strong>practical strategies</strong> for <strong>prioritizing care goals</strong>, <strong>personalizing treatment approaches</strong>, fostering <strong>multidisciplinary teamwork</strong>, and <strong>ensuring patient safety and well-being</strong> in this vulnerable population. </p><p><strong>Don’t miss the conversation!</strong>  </p><p>The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.  </p><p><strong>Declaration of conflict of interest: </strong>  </p><p><strong>Dr. Jeremy Gilbert:</strong> </p><ul><li>Direct financial relationship, including receipt of honoraria: CPD Network, LMC Canada Inc., CSEM, S&amp;L Solutions, liV Agency, Unik Agency, STA. Membership on advisory boards or speakers’ bureaus: AstraZeneca, Abbott, Amgen, Bayer, Insulet, Tandem, Boehringer Ingelheim, Eli Lilly, GSK, HLS Therapeutics, Novartis, Novo Nordisk, Sanofi. </li></ul><p><strong>Dr. Peter Lin:</strong> </p><ul><li>Direct financial relationship, including receipt of honoraria: AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, MDBriefCase, Canadian Heart Research Centre, CCRN, CHIEF, LMC Diabetes &amp; Endocrinology Group, Diabetes Canada, Novo Nordisk, HLS Therapeutics, Medexus Pharmaceuticals, Pri-Med Canada, liV Agency, MEDUCOM Health, The Rounds, Medscape. Membership on advisory boards or speakers’ bureaus: AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, MDBriefCase, Canadian Heart Research Centre, CCRN, CHIEF, LMC Diabetes &amp; Endocrinology Group, Diabetes Canada, Novo Nordisk, HLS Therapeutics, Medexus Pharmaceuticals, Pri-Med Canada, liV Agency, MEDUCOM Health, The Rounds, Medscape. </li></ul><p>MAT-CA-2500991 </p>